Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
Abstract PURPOSE: The efficacy and tolerability of vitamin K antagonists (VKAs) depends on the quality of anticoagulant control, reflected by the mean time in therapeutic range (TTR) of international normalized ratio 2.0 to 3.0. In the present study, we aimed to investigate the association between TTR and change in TTR (ΔTTR) with the risk of mortality and clinically significant events in a consecutive cohort of atrial fibrillation (AF) patients. METHODS: We included 1361 AF patients stable on VKAs (international normalized ratio 2.0-3.0) during at least the previous 6 months. After 6 months of follow-up we ...
Source: Clinical Therapeutics - December 20, 2017 Category: Drugs & Pharmacology Authors: Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Marín F, Lip GYH Tags: Clin Ther Source Type: research

New anticoagulants for Venous Thromboembolism and Atrial Fibrillation: What the future holds.
Authors: Dimitropoulos G, Rahim SMZ, Moss AS, Lip GYH Abstract Introduction The field of anticoagulation has seen impressive progress over the last decade. The introduction of the Non Vitamin K Oral Anticoagulants (NOACs) has revolutionized practice surrounding thromboprophylaxis, treatment of thromboembolic disease and stroke prevention in atrial fibrillation (AF). However, the search for the "holy grail" of anticoagulation, an agent that combines optimal efficacy with minimal bleeding diathesis, continues. Areas covered In this paper we aim to summarize the current evidence from pre-clinical studies and early pha...
Source: Expert Opinion on Investigational Drugs - December 13, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Oral Anticoagulants in German nursing home residents – Drug use patterns and predictors for treatment choice
ConclusionsNOACs are increasingly used in German nursing homes, both for initial anticoagulation but also in VKA pre‐treated patients. Switching from VKA to NOAC was substantially influenced by aspects such as intended higher effectiveness and safety but probably also practicability due to less blood monitoring.
Source: British Journal of Clinical Pharmacology - November 1, 2017 Category: Drugs & Pharmacology Authors: Kathrin Jobski, Falk Hoffmann, Stefan Herget ‐Rosenthal, Michael Dörks Tags: PHARMACOEPIDEMIOLOGY Source Type: research

New Advances In Atrial Fibrillation Management: The Role Of Apixaban.
Abstract Prevention of stroke is a pivotal intervention in the management of patients with atrial fibrillation (AF) at increased risk of systemic embolism. Because of the difficulties of safely implementing Vitamin K Antagonists in all patients, there has been a growing interest in improving the pharmacological management of AF, with newer antithrombotic agents. The new oral anticoagulants (NOACs) have been developed to overcome the limitations and improve the efficacy of the conventional oral anticoagulant drugs. Among the NOACs, apixaban - a very specific antagonist of activated factor Xa - has pharmacokinetic a...
Source: Current Drug Targets - October 12, 2017 Category: Drugs & Pharmacology Authors: Rosano GM, Spoletini I, Gianni W, Vitale C Tags: Curr Drug Targets Source Type: research

Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation
AbstractAtrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic events, which can be effectively prevented using oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, or edoxaban. Until recently, VKAs were the only available means for OAC treatment. NOACs had similar efficacy and were safer than or as safe as warfarin with respect to reduced rates of hemorrhagic stroke or other intracranial bleeding in the respective pivotal randomized clinical trials (RCTs) of stroke prevention in non-valvular AF...
Source: Advances in Therapy - September 27, 2017 Category: Drugs & Pharmacology Source Type: research

How prepared are pharmacists to support atrial fibrillation patients in adhering to newly prescribed oral anticoagulants?
Conclusion Results suggest the provision of NMS for NOACs is low. Supporting pharmacists with tailored education and adherence support might foster dissemination.
Source: International Journal of Clinical Pharmacy - September 5, 2017 Category: Drugs & Pharmacology Source Type: research

The safety of edoxaban for treating atrial fibrillation.
Authors: Hammwoehner M, Goette A Abstract INTRODUCTION: Atrial Fibrillation (AF) has a worldwide increasing incidence and prevalence, putting patients at risk for atrial thrombus formation and consecutive thromboembolic events. Morbidity and mortality have become a significant global public health care burden. Thus, there is increasing need for safe and effective medical prophylaxis of thromboembolic events. Edoxaban is the fourth approved non-vitamin K oral anticoagulant (NOAC) that has been introduced into the market for the prophylaxis of stroke or systemic embolism in non valvulär AF patients after dabigatran,...
Source: Expert Opinion on Drug Safety - September 3, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the French nationwide healthcare databases
ConclusionResults from this nationwide cohort study showed high non‐persistence levels with all OACs and suggest that persistence with both dabigatran and rivaroxaban therapy is not better than persistence with VKA therapy. Hospitalizations for bleeding among non‐persistent patients were unlikely to explain these high non‐persistence rates.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - September 1, 2017 Category: Drugs & Pharmacology Authors: G éric Maura, Cécile Billionnet, François Alla, Joshua J. Gagne, Antoine Pariente Tags: Original Research Article Source Type: research

Once versus twice daily direct oral anticoagulants in non-valvular atrial fibrillation.
Authors: Ageno W, Beyer-Westendorf J, Rubboli A Abstract Introduction Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K antagonists for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Four DOACs: dabigatran, rivaroxaban, apixaban and edoxaban, are currently available. In the absence of head-to-head clinical comparisons of DOACs, dosing regimen may influence drug choice. Areas covered Edoxaban and rivaroxaban are administered once daily, dabigatran and apixaban twice daily. The selection of these dosage regimens is largely based on studies for the prevent...
Source: Expert Opinion on Pharmacotherapy - August 9, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
ConclusionsNOACs are increasingly used in AF patients in the Balkan Region, but NOAC use is predominantly guided by factors other than evidence-based decision-making (e.g., drug availability on the market or reimbursement policy). Efforts are needed to establish an evidence-based approach to OAC selection and to facilitate the optimal use of OAC, thus improving the outcomes in AF patients in this large region.
Source: Advances in Therapy - August 9, 2017 Category: Drugs & Pharmacology Source Type: research

Clinical study on anti-epileptic drug with B vitamins for the treatment of epilepsy after stroke.
CONCLUSIONS: Anti-epilepsy drugs combined with B vitamins can improve epilepsy control after stroke and reduce new stroke occurrence. This effect may be associated with stability of plasma ADMA levels. Vitamin B12 may be better than vitamin B complex in the treatment of epilepsy after stroke. PMID: 28770947 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - August 6, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Effect of Renal Function on Dosing of Non-Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation.
CONCLUSIONS: Inappropriate dosing occurred among patients with normal and insufficient renal function. The consideration of clinical factors beyond renal function is necessary to reduce bleeding risk associated with DOAC therapy. PMID: 28856898 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 1, 2017 Category: Drugs & Pharmacology Authors: Shrestha S, Baser O, Kwong WJ Tags: Ann Pharmacother Source Type: research

Dabigatran and vitamin K antagonists ’ use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records
ConclusionsMost patients recently diagnosed with non-valvular atrial fibrillation initiated treatment with VKA. Primary healthcare patients with non-valvular atrial fibrillation initiating dabigatran are younger, had a lower risk of stroke or bleeding, fewer comorbidity and more history of stroke and intracranial haemorrhage compared to those who were initiated on VKA.
Source: European Journal of Clinical Pharmacology - July 19, 2017 Category: Drugs & Pharmacology Source Type: research

Non-Vitamin K antagonist Oral Anticoagulants: Impact of Non-adherence and Discontinuation.
Authors: Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Lip GYH Abstract INTRODUCTION: Non-Vitamin K Oral Anticoagulants (NOACs) are at least as effective as vitamin K antagonists (VKAs) reducing thromboembolism and mortality in atrial fibrillation (AF). These "fixed-dose regimen" drugs are characterized by not requiring routine monitoring or dosage adjustment. Stroke prevention with OAC is indicated in AF patients with CHA2DS2-VASc ≥2 (≥3 in females) and NOACs are recommended in preference to VKAs. However, underuse, premature discontinuation of treatment and non-adherence to guidelines is common, ...
Source: Expert Opinion on Drug Safety - July 6, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-Analyses.
Abstract PURPOSE: The findings from the observational studies comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) for atrial fibrillation (AF) and venous thromboembolism (VTE) are inconsistent. We conducted separate meta-analyses examining the efficacy/effectiveness and safety of NOACs versus VKAs by disease (AF vs VTE), study design (randomized controlled trials [RCTs] vs observational studies), and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban). METHODS: The main data sources included PubMed/MEDLINE, EMBASE, Web of Scienc...
Source: Clinical Therapeutics - June 28, 2017 Category: Drugs & Pharmacology Authors: Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH Tags: Clin Ther Source Type: research